FDA Approves Lenacapavir, a Groundbreaking HIV Prevention Medicine

Strategic Insights -

The United States Food and Drug Administration has approved Lenacapavir (LEN), a highly effective HIV prevention medicine that can reduce the risk of transmission by 99.9 per cent. This approval has significant implications for global efforts to combat the spread of HIV, particularly in India, where Dr. I.S. Gilada, president emeritus of the AIDS Society of India, believes that accessibility and affordability are key to realizing the full potential of LEN. Lenacapavir is an injectable Pre-Exposure Prophylaxis (PrEP) that is taken twice yearly, and its approval marks a major breakthrough in HIV prevention.

Key Takeaways:

  • Lenacapavir (LEN) has been approved by the FDA as an injectable PrEP that reduces the risk of HIV transmission by 99.9 per cent.
  • The Indian government's National AIDS Control Organisation has yet to roll out PrEP, despite its approval by the US FDA in 2012.
  • Dr. I.S. Gilada emphasized that investing in HIV prevention not only protects people's health but also saves expenses in providing lifelong HIV care.
  • The major impediment to widespread adoption of LEN is its high cost, pricing at $28,218 per person per year, although Gilead has granted voluntary licenses to four Indian generic companies, which may reduce the cost to under $100.
  • India has the capacity to meet global demand for LEN at a low cost, just as it did for ART, at 0.3 per cent of the innovator's cost.
  • Gilead's decision to grant voluntary licenses to Indian generic companies is a significant step towards making LEN more accessible and affordable.

Statistics:

  • 99.9 per cent reduction in HIV transmission risk associated with Lenacapavir (LEN).
  • $28,218: the cost of Lesnacapavir as PrEP per person per year.
  • Under $100: the potential cost of Lenacapavir as PrEP, thanks to Gilead's voluntary licensing agreements with Indian generic companies.
  • 92 per cent: the proportion of the global ART requirement met by India.
  • 0.3 per cent: the cost of generic ART in India compared to the innovator's cost.

Sources:

  • The Indian Express
  • Food and Drug Administration (FDA)
  • AIDS Society of India (ASI)
  • Gilead Sciences
  • World Health Organization (WHO)
  • Joint United Nations Programme on HIV/AIDS (UNAIDS)
  • The Global Fund
  • The World Bank